HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Novel Food Approvals: Yes To Vit D Mushroom Powder, No To New Zinc Source

Executive Summary

Two novel food applications were recently reviewed by the European Food Safety Authority, with one from Monterey Mushrooms for vitamin D2 mushroom powder approved, and another from Hamari Chemicals for a new source of zinc rejected. 

You may also be interested in...



EU CBD Novel Food Applications On Hold As EFSA Considers Health Risks

All European Union CBD novel food applications have been paused by EFSA after its Panel on Nutrition, Novel Foods and Food Allergens raised concerns about the ingredient's safety, pointing in a wide-ranging scientific literature review to a number of data gaps related to bioavailability, liver damage, gastrointestinal issues and possible negative impacts on pregnancy and reproductive health.  

Curcumin Touted For Oral Health Gets EFSA Novel Food Nod

In its latest batch of novel food assessments, the European Food Safety Authority gave the nod to a curcumin supplement touted for its oral health benefits, but rejected applications for flowering plant Tongkat Ali and water lentil Wolffia globosa.

‘Beneficial Bacteria’ Gets Novel Food Approval From EFSA

EFSA has given a positive opinion on the safety of Akkermansia muciniphila as a novel food. Naturally occurring in the human gut, A. muciniphila can help to control fat storage and glucose metabolism, claims applicant A-Mansia.

Topics

Latest News
UsernamePublicRestriction

Register

RS152657

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel